NTRA News and Press, Natera Inc. From 10/22/23

Builds on published evidence with twice as many patients and disease-free survival data extended to 24 months Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced updated data from the GALAXY arm of the CIRCULATE-Japan trial further showcasing the a...

NATERA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Natera, Inc. - NTRA NATERA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Di...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its third quarter ended September 30, 2023, after the market close on Nov. 8, 2023. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has been named by U.S. News & World Report as one of the best companies to work for in healthcare. Natera was ranked among 349 companies across 20 fields of work on factors contributing to job...

2023-10-17 09:15:48 ET Palm Beach, FL – October 17, 2023 – FinancialNewsMedia.com News Commentary – Multiple myeloma is a type of cancer that affects plasma cells, which are a type of white blood cell that produces antibodies to fight infections. The US mult...

Presentations include largest analysis from the GALAXY study in colorectal cancer with updated 24-month disease-free survival data, and expanded Signatera readout in rectal cancer Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced it will present ...

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Natera, Inc. (NasdaqGS: NTRA). On March 14, 2022, a jury found that the Company intentionally...

Test performance showed 82% pre-treatment detection, with 100% longitudinal sensitivity and 100% longitudinal specificity to disease progression Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Frontiers in Oncology ...

2023-10-03 18:04:45 ET More on Natera, CareDx Natera: Strong Growth Amidst Profitability Challenges CareDx wins injunction against Natera in false advertising case Natera announces $250M common stock offering For further details see: Natera prevails in pa...

Final decision follows multiple previous court rulings in favor of Natera and upholds invalidation of CareDx patents Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that the United States Supreme Court denied CareDx, Inc.’s (NASD...